fda compounding semaglutide warning letters october 2025 Letter Breakdown: Sterility Failures, Subpotent GLP-1 Drugs, and a Pharmacy Operating Without Control February 17, 2026: Pennsylvania compounding

Continuing this discussion, we broaden the lens to the developing litigation environment and additional regulatory scrutiny that can affect manufacturers, pharmacies, telehealth providers, and other stakeholders across the GLP1 ecosystem

Lose weight with proven GLP-1 medications through our trusted telehealth clinic

A BMI of 30 kg/m or greater (with obesity) or

Find out more today.

Heart palpitations can be a concerning and uncomfortable experience for many individuals

Patients initiated on GLP-1 receptor agonists should be evaluated every 3-6 months after reaching their maintenance dose, with more frequent monitoring (mont...